FDA Oncology Announcements

JAK inhibitor × Clear all

5 Announcements

FDA approves ruxolitinib for chronic graft-versus-host disease

Drug: Jakafi (ruxolitinib) · JAK inhibitor
Condition: Other

FDA approves fedratinib for myelofibrosis

Trial: JAKARTA
Drug: INREBIC (fedratinib) · JAK inhibitor
Condition: Myeloid

FDA approves ruxolitinib for acute graft-versus-host disease

Drug: JAKAFI (ruxolitinib) · JAK inhibitor
Condition: Other

FDA Approves Ruxolitinib

Drug: Jakafi (ruxolitinib) · JAK inhibitor
Condition: Myeloid

Ruxolitinib

Drug: Jakafi oral tablets (ruxolitinib) · JAK inhibitor
Condition: Myeloid